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Abstract
Despite being a “silent epidemic” disease, chronic kidney disease (CKD) is considered 
one of the major causes of mortality, together with its main complication, the cardiovas-
cular disease, which contributes to the poor prognosis of these patients. Inflammation 
has been recognized as an essential part of CKD and is closely linked to cardiovas-
cular complications. The identification of novel biomarkers using omics technologies 
is rapidly advancing and could improve the early detection in renal diseases. Omics 
approaches, including proteomics, could provide novel insights into disease mecha-
nisms, identifying at the same time accurate inflammatory biomarker panels with an 
essential role in disease monitoring and follow-up. Recent advances highlight the gut 
microbiota as an important source of inflammation in kidney diseases. An increasing 
body of evidence reveals the cross talk between microbiota and host in CKD; in addi-
tion, gut dysbiosis may represent an underappreciated cause of inflammation and 
subsequently could lead to malnutrition, accelerated cardiovascular disease and CKD 
progression. This chapter discusses the relationship between inflammation and CKD 
and highlights the novel approaches regarding microbiota involvement in CKD pathol-
ogy, as well as their potential to facilitate improving the quality of life.
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1. Introduction
Chronic kidney disease (CKD) is defined, according to KDIGO 2017 Clinical Practice Guide­
line Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney 
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Disease–Mineral and Bone Disorder (CKD-MBD), as “abnormalities of kidney structure or 
function, present for more than 3 months, with implications for health.” CKD is classified 
based on pathological cause, glomerular filtration rate category (from G1, normal, to G5, kid-
ney failure), and albuminuria category (from A1, <30 mg/g, to A3 > 300 mg/g) [1]. It will 
inexorably lead to end-stage renal disease, unless managed as to address treatment of the 
underlying condition, diagnosing and treating the pathologic manifestations and timely plan-
ning for long­term renal replacement therapy. A recent systematic review and meta­analysis 
of observational studies revealed that CKD has an estimated global prevalence between 11 
and 13%, with the majority of cases in stage 3 [2]. The complexity of CKD pathogenesis is 
underlined by a plethora of risk factors: genetic and epigenetic age [3], low birth weight, 
socioeconomic status, obesity [1], smoking and/or hypoxia [4], and vascular factors, induced 
by atherosclerosis [5], hypertension [6], and diabetes mellitus [7]. Furthermore, the compli-
cations of this disease also impact beyond the kidney, with cardiovascular burden (such as 
coronary artery disease, congestive heart failure, arrhythmias, and sudden cardiac death) as a 
major mark [8]. CKD associates also with enhanced formation of atherosclerotic plaques [9]. 
Other complications include endocrine dysfunctions involving hormones that control calcium 
[10] and phosphate balance [11], vitamin D metabolism, and, consequently, bone mineraliza-
tion defects [12]. Hemodialysis patients are further at risk for cardiovascular complications, 
such as vascular overload leading to arterial stiffness [13] or, apparently paradoxical, isch-
emia induced by repeated episodes of hypovolemic hypoperfusion during hemodialysis [9].
Inflammation has been recognized as an essential part of chronic kidney disease (CKD) since 
the late 1990s and is now considered a well­established risk factor for this pathology [14], as 
well as for other renal pathologies. In fact, inflammation is now considered a key player in dif-
ferent major pathologies such as cardiovascular disease [15], neurodegeneration [16], or cancer 
progression and survival [17]. Chronic systemic inflammation, sometimes referred to as low­
grade chronic inflammation, is characterized by 2–3 fold increase of circulating inflammatory 
mediators (such as interleukins 1, 6 tumor necrosis factor, and their soluble receptors), slow 
developing, persistent and of multifactorial origin, sometimes difficult to identify [18]. Recent 
findings associate chronic systemic inflammation with alteration of gut microbiota, which is 
in permanent cross talk with the immune system. This cross talk is essential for maintenance 
of a tolerant immune response toward commensal flora and elimination of pathogens [19]. 
Intestinal dysbiosis is detrimental for health in ways overpassing the intestinal environment, 
from production of toxic metabolites, overconsumption of energy, and molecular mimicry 
of host proteins [20]. This chapter will present an up­to­date findings relating to chronic sys-
temic inflammation and CKD, with emphasis on gut dysmicrobism involvement and whether 
intervention on gut microbiota could be proven beneficial for the outcome of this fatal disease.
2. Inflammation and its impact on CKD progression: an update
Persistent, low­grade inflammation is considered crucial component of CKD, having a huge 
contribution to the development of all-cause mortality related to renal disease. There has been 
an ascending growth of interest regarding the role of inflammation in CKD and end­stage renal 
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disease (ESRD), which shifts the perception of inflammation as no longer a new, but rather a tra-
ditional risk factor for CKD morbidity and mortality [14, 21]. A challenging theory regarding the 
direct effect of inflammation on the progression of both CKD and cardiovascular disease came out 
with the assumption of association between markers of inflammation, changes in GFR and nutri-
tion habits in elderly individuals. It was found that the deterioration in renal function (alteration of 
GFR, urea and creatinine) was associated with an increasing number of markers of inflammation 
and thrombosis [22]. Regardless of a genetic background, CKD is a condition that accelerates pre-
mature aging through diverse mechanisms in the internal milieu, counting DNA damage, inflam-
mation, low Klotho expression, redox perturbations, toxicity, and local signaling of growth factors 
[23]. It is generally known that there is a heterogeneous distribution of intrarenal vasculature in 
normal conditions, and only medulla is under hypoxic conditions. In order to bypass energy depri-
vation in the deficient pO2 parts of the kidneys, an avalanche of mediators is involved to regulate 
the complex processes, including hormones, autocoids, and vasoactive substances: medullipin, 
prostaglandins, endothelins, nitric oxide, angiotensin II, kinins, and adenosine. A state of sus-
tained inflammation could surely alter the microvascular feedback to its regulators and could acti-
vate the reaction of an array of tubular toxins, including reactive oxygen species (ROS), generating 
further renal failure [24]. The highly reactive ROS could alter different structures and functional 
pathways in cells, and, as a repercussion, a vicious circle arises, in which the inflammatory cells 
are stimulated by cell damage caused by ROS, giving birth to a state of oxidative stress. The com-
mon oxidant “imbalance” theory is remarkably completed with recent advances regarding the 
cross talk between oxidants and antioxidants; the reasoning for antioxidant therapies consists thus 
in repairing the imbalances in the redox environment of cells [25]. The old theory suggesting the 
oxidative stress as a “unifying concept of cardiovascular disease in uremia” [26] is continuously 
enriched, and novel molecules, belonging to the Paraoxonase family, are suggested as potential 
biomarkers. Paraoxonase­1 seems to have a protective effect against lipoprotein oxidation and its 
expression is decreased in CKD patients, being a marker for antioxidant status [27]. The develop-
ment of specific redox proteomic techniques will facilitate the implementation of new preventive 
and therapeutic strategies to fight against atherosclerosis and other metabolic diseases [28].
In comparison with the well­established clinical markers, proteomic biomarkers could offer an 
accurate and earlier detection of renal pathology. Although the “breaking point” could be vari-
ous in different patients, in some populations, the circulating creatinine levels fall into normal 
ranges despite loss of more than 50% of renal function, so supplementary biomarkers of renal 
function are desired. Recent studies conclude that a cross talk between inflammation, bone, 
vasculature, and renal function exists in CKD. In early stage 2 of CKD, an increased expres-
sion of a panel of proteomic biomarkers was observed, including IL­6, TNF­α, osteoprotegerin, 
osteocalcin, osteopontin, and FGF­23, which, at a first glance, highlights the hope of improving 
the management of patients with CKD starting with early stages, which is an area to focus 
research in the near future [29]. Another study evaluating the association between kidney func-
tion, albuminuria, and biomarkers of inflammation in a large cohort of CKD patients showed 
that plasma levels of IL­1β, IL­1RA, IL­6, TNF­α, hs­CRP, and fibrinogen were higher among 
participants with lower levels of estimated glomerular filtration rate (GFR). Moreover, inflam-
mation score was higher among patients with lower estimated GFR and higher urine albumin 
to creatinine ratio (UACR). These results demonstrated that biomarkers of inflammation were 
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inversely associated with measures of kidney function and positively with albuminuria [30]. 
The erythrocyte sedimentation rate, a nonspecific measure of inflammation, has been shown to 
be predictive of end­stage renal disease in adolescents [31]. The level of pro­inflammatory cyto-
kine IL­2 was elevated in hemodialysis patients with uremic pruritus (a common tormenting 
symptom among these patients) when compared to hemodialysis patient controls without pru-
ritus [32]. The results obtained from several researches suggest that tumor necrosis factor-like 
weak inducer of apoptosis (TWEAK) plays an important role in kidney injury associated with 
inflammation and promotes acute and chronic kidney diseases [33]. There are several studies 
testing different nanoconjugates that could prevent TWEAK­induced cell death and inflam-
matory signaling in different cell types, including renal tubular cells [34]. The results obtained 
from a study investigating hemodialysis patients showed that the group of patients with a 
specific pattern of high pro­inflammatory cytokines (IL­1, IL­6, and TNF­α) had increased mor-
tality when compared to patients with a pattern of high T­cell regulatory or anti­inflammatory 
parameters (IL­2, IL­4, IL­5, IL­12, CH50, and T­cell number) [35].
Availability of omics multiplex technology offered the opportunity of shifting the analy-
sis of single individual marker toward assessing cytokine panels [36]. It was described an 
inflammatory panel, consisting of pro­inflammatory cytokines IL­1, IL­6, and TNF­α with 
anti­inflammatory ones IL­2, IL­4, IL­5, IL­12, CH50, as well, with a significant impact on 
CKD patients’ survival [35]. Recently, significant attention has been granted to the poten-
tial role of adipokines in CKD, such as pro­inflammatory leptin, apelin, omentin, visfatin, 
resistin, and anti­inflammatory adiponectin. Based on the data from the National Health 
and Nutrition Examination Survey (NHANES), it was shown that CKD is correlated with 
increased leptin levels [37]. Moreover, adiponectin expression in ESRD patients was also sig-
nificantly increased compared to healthy individuals [14].
Atherosclerosis is now considered a chronic inflammatory disease and, in turn, cardiovascular 
disease is a major complication of CKD. Thus, a vicious circle is created between inflammation 
and CKD. Atherosclerosis is accelerated in CKD by complex mechanisms involving a cross talk 
between lymphocyte T helper type 1 and subendothelial macrophages as antigen presenting cells. 
The triggers of this cellular response are alteration of lipid metabolism and subendothelial deposit 
of plasma lipoproteins. Locally recruited lymphocytes react to autoantigens from the apolipopro-
tein B100 protein of LDL, generating an inflammatory response [38]. Within the predialysis CKD 
patients, the prevalence of inflammation is increasing and represents a critical indicator of patient 
health and future outcome. In ESRD, the process of hemodialysis itself may contribute to the pro-
inflammatory state, and different types of dialysis membrane could determine an inflammatory 
response. However, hemodialysis does not represent the only source of inflammation, since the 
predialysis CKD patients already manifest a certain inflammatory state [39]. A persistent inflam-
matory state in CKD is not only linked to cardiovascular complications but is also one of the key 
players in the development of malnutrition/protein­energy wasting, having as consequence the 
malnutrition­inflammation­cachexia syndrome in CKD/ESRD patients. It was also described, in 
a cohort of dialysis patients, that circulating levels of IL­1 and IL­6 could suppress the PTH secre-
tion, which, in turn, may reflect the malnutrition­inflammation­cachexia syndrome, rather than 
the low bone turnover disease [40]. The pathophysiology of inflammation could be different with 
regard to different racial, ethnic, or genetic features. Recent studies specify that dietary habits 
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could add a peculiar signature to the gut microbiota composition, and intestinal dysbiosis itself 
could thus interfere with the inflammatory mechanisms in CKD population.
In summary, persistent low­grade inflammation has been recognized as an important compo-
nent of CKD scenario, playing major roles in the pathophysiology of the disease, with a major 
imprint on its complications. Nevertheless, further investigations are necessary to decipher 
the role of inflammation in CKD population, particularly in the early stages.
3. The role of inflammation in the development of cardiovascular 
diseases in CKD
Cardiovascular disease represents one of the main determinants of CKD’s poor prognosis, 
since early stages of CKD are significantly correlated with increased risk of subsequent cor-
onary heart disease [41]. In agreement with several clinical studies, approximately 50% of 
patients with CKD have a rising mortality due to the cardiovascular complications, such as 
advanced calcific arterial and valvular disease; however, the mechanisms that involves the 
accelerated calcification in CKD continue to be questionable, thus no specific therapies have 
emerged to target the disease prevention [42].
The current CKD guidelines are recommending the screening for vascular calcification (VC), for 
the reason that VC represents a cardiovascular risk factor, and it is correlated with an increased 
morbidity and mortality in CKD group, culminating in CKD stage 5. Vascular calcification is now 
considered an active process that involves many proteins, as possible candidate markers [43]. In 
CKD individuals, several studies have highlighted various circulating biomarkers that could 
play important roles in extra­skeletal calcification and mineral metabolism alterations, which 
are considered characteristics of CKD­mineral bone disorder (CKD­MBD) [44]. As a result, these 
findings have revealed that CKD­MBD comprises laboratory and bone abnormalities and vascu-
lar calcification and has deleterious consequences on clinical outcomes; however, these processes 
are interconnected and they have to be studied in association with cardiovascular diseases [1].
Cardiovascular calcification represents though an exceptional marker of chronic inflammatory 
status in CKD, strongly correlated with morbidity and mortality. Curiously, CKD accelerates 
the atherosclerosis evolution and it has been showed that CKD produces increasing vascular 
inflammation and calcification. Recent advances highlighted the potential involvement of matrix 
vesicles (secreted by macrophages), as key molecules in the alternative processes independent of 
osteogenic differentiation [45]. Deciphering the association between these mechanisms and sig-
naling pathways could bring novel insights into the mechanistics of calcification and could pos-
sibly move forward to new therapeutic strategies aiming at cardiovascular disease in CKD [46]. 
These findings are in concordance with the genetics, and it was shown that 40–50% of coronary 
calcification cases could be linked to genetic predisposition, considering that several loci were 
linked to coronary arterial calcification [47]. The involvement of single polymorphisms located 
at 9p21 locus near the cyclin genes was proposed as a genetic mechanism of this pathology; 
the concerned genes could be generally associated with cellular senescence and inflammation, 
although the accurate causative DNA sequences continue to be uncertain [48]. Recent evidence 
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suggests that the overlap between CKD and cardiovascular disease is due, on one hand, to the 
dynamic cross talk between these organs, resulting in cardio-renal syndrome, increasingly rec-
ognized [49] and, on the other hand, it could be linked to the common etiologies of these major 
diseases (hypertension and diabetes mellitus). It has also been investigated as a possible com-
mon disorder of the kidneys and heart whereby acute or chronic dysfunction in one organ may 
induce acute or chronic dysfunction in the other organ; nevertheless, a complete picture of the 
mechanisms implicated in these processes is still missing [49]. The highly reactive oxygen species 
(ROS) present the potential of disrupting different structural and functional pathways in cells. 
Therefore, the inflammatory cells are activated by cell damage produced by ROS; thus, a vicious 
circle of chronic disturbance is constantly perpetuated. The oxidant imbalance theory comprises 
several important pathways and cell metabolism also has been under the surveillance of the 
cross talk between oxidants and antioxidants. The role of oxidative stress in the pathogenesis of 
CKD relies though on the hypothesis that antioxidant therapies could target and reconstruct the 
disturbances in the redox environment of cells [50]. Different therapeutic strategies have been 
considered to decrease oxidative stress (OS) in models of CKD and cardiovascular disease, pro-
posing a low oxidant intake in different dietary approaches. Oxidative stress and inflammation 
increase with aging, and these conditions are related to kidney failure in its early stages, as well. 
There are evidences that a diet supplemented with oxidants could produce increased serum 
levels of OS and inflammatory mediators in both normal aging and in CKD. It is mentioned that 
dietary intervention could offer novel therapeutic strategies by reducing OS and inflammation 
in patients with CKD and in aging population with decreased kidney function [51].
Due to the circulating nature of many inflammatory mediators (cytokines and immune cells), it 
is tempting to hypothesize that the immune system could have crucial roles in organ interactions 
and could mediate the reciprocal dysfunction that is experienced in cardio-renal syndromes.
4. Omics technologies and clinical relevance of proteomic 
biomarkers in renal diseases: rolling proteomics into clinics
Over the last decade, there has been an increasing progression of omics approaches, accompa-
nied by remarkable improvement of methodologies and analytical instruments, based on the 
concept that a thorough characterization of a complex system, providing novel perceptions 
into functional pathways and regulatory networks, could be deciphered in frame of these 
omics. In the light of recent advances in bioinformatics and biostatistics on state-of-the-art 
platforms, the access of scientists in correlating the experimentally observed data regarding 
the fundamental biochemical and pathological mechanisms was facilitated [52, 53]. Proteomic 
biomarkers in kidney disease may represent, along with classical markers serum creatinine 
and urinary albumin, valuable tools in clinical diagnosis due to their accurate potential for 
clinical implementation. Moreover, proteomic biomarkers could also be useful in character-
izing the most suitable therapeutic targets in a given patient or disease setting [54].
The huge step forward was accomplished by coupling liquid chromatography with mass spec-
trometry, enabling untargeted protein identification. Additionally, capillary electrophoresis had 
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also an accelerated development in the last years, being able to rapidly separate analytes in a 
highly reproducible manner [55]. Also, matrix­assisted laser desorption/ionization (MALDI) plat-
form has moved the boundaries above, being able to assess tissue specimens with high resolution 
in order to discriminate individual cells. This approach can provide detailed information related 
to CKD and the potential to detect specific biomarkers. Recent evidence suggests that MALDI 
could generate molecular signatures of primary and secondary kidney injury, with one particu-
lar signal, identified as serine/threonine­protein kinase MRCK gamma, being overexpressed in 
the glomeruli of primary membranous nephropathy (MN). These findings could be potential 
future targets for the further stratification of these patients [56]. Other studies emphasize the role 
of omics technologies, including MALDI to generate molecular signatures capable to distinguish 
between normal kidney and pathological kidney, with specific signals representing potential 
indicators of CKD development [57]. Kidney and Urinary Pathway Knowledge Base (KUPKB) 
represents an open source to explore multi-omics data and to generate new in silico theories using 
a novel approach based on semantic web technologies [58]. Moreover, CKDdb represents the 
most comprehensive molecular information resource in characterizing CKD-related experiments 
and model systems, potentially useful in the design of disease models, thus avoiding the chal-
lenges related with handling and integration of heterogeneous enormous data [59].
The emerging knowledge generated by the application of omics (genomics, proteomics, and 
metabolomics) in major diseases, including CKD, could provide new insights into the patho-
physiology of the disease by identifying novel biomarkers that could improve, in real time, 
the early diagnostics, monitoring, and prognostics; thus, omics will provide a major impact in 
the field of personalized medicine [60].
5. Gut microbiota as a source of inflammation in CKD: 
a bidirectional relationship
Accumulating evidence over the recent years has highlighted that chronic inflammation rep-
resents a nontraditional risk factor in CKD population and was revealed that gastrointestinal 
tract is a major player in systemic inflammation occurring in CKD [61]. The gut microbiota 
preserves the symbiotic relationship with the host in normal conditions and is essential for 
regulation of local and systemic immunity [62], although its imbalance has latterly been related 
with several diseases [63]. Alteration in the functions or signaling pathways of the commensal 
flora contributes to the pathogenesis of diverse diseases, including chronic inflammation and 
renal disorders, as well; gut bacterial DNA fragments have been detected in the blood of both 
predialysis CKD and chronic hemodialysis patients [64]. The decisive role of the biochemical 
milieu in shaping the gut microbiota, in terms of structure, composition, and function, which 
could promote a proinflammatory activity, was also described and it could simultaneously 
restrict the beneficial effects offered by a balanced microbiota. Such conditions could lead 
to an altered status, targeting inflammation, uremic toxicity, and other complications inside 
the CKD patients [65]. The interactions are bidirectional: on the one hand, uremia negatively 
interferes with the microbiota, altering the composition and metabolism and, on the other 
hand, the microbiota dysbiosis releases compounds that are normally excreted by the kidneys 
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but could be considered as potential uremic toxins, both conditions further leading to a toxin 
avalanche exposure, due to the disruption of the epithelial barrier with an increased intestinal 
permeability, often referred to as “leaky gut,” a condition that has been reported in CKD [66].
Uremia status seems to impair the intestinal barrier function and promotes inflammation 
throughout the gastrointestinal tract. A prospective, observational study reported the base-
line concentration of indoxyl sulfate, a uremic toxin that could have a predictive power in 
CKD progression [67]. Other uremic toxins, p-cresol sulfate and trimethylamine N-oxide 
(TMAO), were assessed in relation to kidney function (estimated GFR), and the results con-
clude that the elevated expression was associated to an increased risk for all-cause mortality 
in ESRD patients. [68]. Uremia represents a condition that accompanies kidney failure and 
CKD. Uremic toxins originated in, or inserted into, the body via the intestine, such as glyca-
tion metabolites, phenols, indoles, all may play important roles in CKD pathophysiology. 
Consequently, it is biologically plausible, but not well accepted, that a crucial player in the 
toxic scenario of the CKD resides in the gut microbiota [69].
Deciphering the role of gut microbiota in CKD progression needs a complex comprehension 
regarding its composition, function, and homeostasis within each individual. As expected, 
the gut microbiota composition shows great variations, representing a unique signature with 
each individual harboring, consisting mainly of Gram­negative Bacteroidetes and the Gram­
positive low­GC Firmicutes [68]. Gut dysbiosis in CKD was correlated with an increase in 
pathogenic flora compared to symbiotic flora, which, along with enhanced intestinal per-
meability, increases absorption of endotoxins with harmful consequences in the organism. 
The gut-derived uremic toxins, along with an expanded permeability of the intestinal barrier, 
have been correlated with an increased inflammatory state and oxidative stress, which are 
constant features of advanced CKD, with a major impact on its complications [65]. The dys-
biotic intestinal microflora could be correlated to the intestinal wall edema and ischemia, as 
well as to a defective colonic epithelial barrier [65]. Recent evidences suggested that several 
circulating metabolites derived from gut microbiota metabolism could be related to systemic 
immunoinflammatory response and kidney damage. It has been shown that short­chain fatty 
acids (SCFAs), which are metabolites essentially derived from dietary fiber fermentation in 
the gut, are significant players in modulation of immunity, blood pressure, glucose, and lipid 
metabolism. In addition, SCFAs also “modulate different cell signal transduction processes 
via G­protein–coupled receptors and act as epigenetic regulators by the inhibition of histone 
deacetylase and as potential mediators involved in the autophagy pathway.” Though contro-
versial, the SCFAs may be regarded as potential therapeutic targets and seem to represent the 
link between kidney damage and inflammatory response [70]. Gut inflammation is prevalent 
in CKD and is subsequently involved in systemic inflammation by disruption in the epithelial 
tight junction, leading to endotoxin and bacterial translocation; this state is associated with a 
defective Nrf2 pathway. On the basis that Nrf2 represents a protein that regulates the expres-
sion of antioxidant proteins that protect against oxidative damage triggered by injury and 
inflammation, oral administration of Nrf2 activator (study conducted on rats) has reestab-
lished the epithelial tight junction protein expression, alleviating arterial hypertension and 
rehabilitating the markers of kidney function [71].
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In conclusion, accumulating evidence recognizes that dietary fiber may reverse gut dysbiosis 
and abolish microinflammation, being in agreement with epidemiological evidence suggesting 
correlations between higher dietary fiber intake, better kidney function, and lower inflam-
mation, at least in the general population. Many researchers accept that supporting intestinal 
health and restoring the integrity of the gut wall will represent one of the most important 
goals in improving the quality of life within CKD individuals.
6. Restoring microbiota balance: the exploration of novel therapeutic 
avenues in renal diseases
Intestinal inflammation and gut microbiota dysbiosis, as well, are now recognized as impor-
tant contributors in chronic inflammation and other CKD complications, thus explaining the 
gut­therapeutic novel avenues taken into consideration in designing CKD interventions [61] .
The microbiota can be considered as a recently discovered “organ,” being involved in many 
pathological axes, in relation with almost every organ, including kidneys; there are different 
metabolites derived from microbiota dysbiosis engaged in distinct physiology pathways link-
ing to renal dysfunction [72]. The bidirectional relationship between gut microbiota and CKD 
is noted in many studies, and the effect of CKD on gut structure, leading further to dysbio-
sis (Figure 1) is also mentioned. The abundance of specific bacterial groups are dominated 
by Bacteroides, Prevotella, or Ruminococcus in normal individual gut microbiota [73], and 
these enterotypes are markedly correlated with long-term diets, especially the proteins and 
Figure 1. The crosstalk between CKD and inflammation in correlation with microbiota dysbiosis modulation.
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animal­fat level (Bacteroides) versus carbohydrates (Prevotella) [74]. On the other side, the gut 
microbiota in CKD patients is altered, particularly with a decreased amount of Lactobacillaceae 
and Prevotellaceae families, and with an increased amount (more than 100 times higher) of 
Enterobacteria and Enterococci, species that are normally found in lower concentrations in 
healthy individuals [65]. The “supplementary organ” has also an important contribution to 
digestion, using two different catabolic pathways: saccharolytic (fermentation), with a high 
prevalence of Bifidobacteria and Lactobacilli, having short­chain fatty acids as end products, 
and the second, proteolytic (putrefaction) pathway, involving some species within Clostridium, 
Bacteroides, Enterobacterium, Bifidobacterium, and Lactobacillus [75] that leads to short or 
branched­chain fatty acids and other cometabolites, considered as microbial uremic toxins [76]. 
Another controversial mechanism linked to microbial dysbiosis in CKD patients involves the 
elevated gastrointestinal urea secretion, leading to important amounts of ammonia, which, in 
turn, contribute to the disturbance in the commensal bacteria [77]; therefore, targeting the gut 
microbiota composition could represent a promising approach in CKD monitoring and follow-
up. Hence, it is considered that a balanced microbiota is mainly saccharolytic and therefore diet 
itself owns a beneficial role in modulating the gut microbiota composition [78].
Key mechanisms to preserve the gut microbiota balance are considered to include special diets, 
such as Mediterranean diet, (detailed in Table 1) enriched in nondigestible carbohydrates, 
subject to fermentation by gut microbiota, with low quantities of proteins or fats [75]. It was 
also revealed that dietary content and their metabolites, such as advanced glycated end prod-
ucts (AGEs), types of uremic toxin resulted in the glycation process, could be closely linked 
to CKD. Promising therapeutic targets based on nutrition approaches include uremic toxin 
absorbents and inhibitors of AGEs or the receptor for AGEs. Also specific types of amino acids 
(d­serine) or fatty acids (palmitate) have been indicated to be related with CKD progression, 
but they are preliminary results and further studies are needed to confirm their efficacy [79]. 
It is worth mentioning that dietary interventions could increase the quality of life in CKD 
patients, though their certain effects on mortality, cardiovascular events, and ESRD remain 
unclear [80]. The significance of a proper diet was settled in large retrospective cohort studies, 
which evidenced that the mortality occurrence in predialysis patients that were under dietitian 
surveillance decreased 19% compared with the patients not under any dietary treat. The con-
clusion that emerged is that a nutritional care in early stages of CKD could have a better prog-
nosis on survival; however, randomized clinical trials are needed to prove this hypothesis [81].
Another area of potential beneficent therapies in CKD patients relies on the administra-
tion of prebiotics and probiotics, and the combination of both therapies into “synbiotic” 
preparations [81].
Probiotics are defined as “live microorganisms that when administered in adequate amounts 
confer a health benefit on the host” [82]. Probiotics consist of living bacteria, which can 
reshape gut microbiota, with impact on the inflammatory status, and are mainly represented 
by Bifidobacteria species, Lactobacilli, and Streptococci. A study on mice revealed that treat-
ment with Lactobacillus acidophilus could have the potential to attenuate the development of 
atherosclerotic lesions in mice by reducing the oxidative stress and the inflammatory response 
[83]. However, the optimal dose of the bacteria essential to obtain an impeccable engraftment 
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and the suspicion whether these bacteria will resist in the uremic habitat remain questionable 
[84]. A multinational trial involving patients with CKD stage 3 and 4 has described that half 
year treatment with proprietary formulation of S. thermophilus, L. acidophilus, and B. longum 
over has induced a significant decline in urea nitrogen circulating levels and has also enhanced 
the quality of life scores in these patients. It still remains unclear whether the described inter-
ventions may alter the integrity of gut tight junction barrier; thus, more studies are needed to 
enlarge the knowledge in this area [85].
Dietary type Diet summary Effects on CKD References
Mediterranean diet Carbohydrates, basically 
unrefined grains, fruits and 
vegetables, nuts, olive oil, fish, 
and a moderate consumption of 
red wine, dairy products, and 
red meats
PROTECTIVE: potentially restoring 
microbiota balance, ameliorating 
CKD conditions, slow down disease 
progression.
[78, 91, 92]
Vegetarian diet Fruits and vegetables, olive oil ADDITIONAL BENEFITS: reduce 
the burden of uremic toxins; 
attention must be paid to serum 
potassium levels.
[93, 94]
Vegan diet Fruits and vegetables, olive oil POSITIVE: the addition of inulin 
modulates microbiota metabolism 
and the high fiber intake of vegan 
diet may have favorable effects on 
intestinal microbiota.
[93]
DASH diet Consistent with a dietary 
approach to hypertension
PROTECTIVE: decreased risk of 
rapid eGFR decline.
[95, 96]
Modern dietary pattern High intake of fruit, soy milk, 
egg, milk, and deep-fried 
products
PROTECTIVE: inversely associated 
with CKD.
[97]
Western diet Excessively rich in protein and 
low in fruit and vegetables, 
grains, and fibers
DETRIMENTAL: increased risk of 
rapid eGFR decline.
[96]
Southern diet Fried foods, organ meats, 
sweetened beverages
Rice, pork, and vegetables, and 
low intake of wheat
DETRIMENTAL: independently 
associated with mortality in persons 
with CKD.
[98]
[97]
Modern dietary pattern, 
with increased cadmium 
intake
High intake of fruit, soy milk, 
egg, milk, and deep-fried 
products, with cadmium 
contamination in parts of the 
food supply
DETRIMENTAL: directly associated 
with CKD.
[97]
DGA diet Diet based on Dietary 
Guidelines for Americans 
(DGA)
DETRIMENTAL: rapid kidney 
function decline.
[99]
DAL diet Diet enriched in dietary acid 
load
DETRIMENTAL: increased risk of 
ESRD and mortality.
[100–103]
Table 1. Different dietary patterns assessed in association with CKD.
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Prebiotics, specialized plant fibers that promote the growth of healthy bacteria in the gut, have 
also an important role in preventing CKD progression [84]. The candidate prebiotics comprise 
inulin, fructo-oligosaccharides, galacto-oligosaccharides, soya-oligosaccharides, xylo-oligosac-
charides, and pyrodextrins and have potential in promoting the growth of Bifidobacteria and 
Lactobacilli species [86]. Recent evidence indicates that prebiotic oligofructose-enriched inulin 
(p­inulin) improves metabolic function, reduces inflammation, and mediates also weight loss 
[79]. Other prebiotic studies have described the role of supplements containing fructo-oligo-
saccharides (FOS) and/or inulin and their potential role in modulating the gut microbiota [75]. 
Prebiotic supplementation with FOS was correlated with a decline in proteolytic metabolites; 
thus, potential prebiotics such as AXOS could significantly imbalance the protein/carbohy-
drate fermentation ratio, resulting in alterations in the profile of fermentation metabolites, but 
the modifications related to microbiota composition remain ambiguous [87, 88].
Synbiotics represent the dual approach of combining a probiotic with a prebiotic and were the 
subject of several studies. The Synbiotics Easing Renal Failure by Improving Gut Microbiology 
(SYNERGY) Study was a single­center, double­blind, placebo­controlled, randomized cross­
over trial that tested the effects of synbiotics in CKD patients with moderate to severe stages 
[89]. In this study, preliminary results highlighted that administration of synbiotic therapy did 
result in appreciable decreasing in circulating levels of nephrovascular uremic toxins, being 
accompanied by a significant modulation of the stool microbiome (especially with enhancement 
of Bifidobacterium and deficiency of Ruminococcaceae) in CKD patients, not under antibiotics 
prescription [89]. The gut microbiota alteration in CKD produces the release of indoxyl sulfate 
and p-cresyl sulfate, which represent key uremic nephrovascular toxins. Emerging evidence 
reveals that gut microbiota modulation through diet supplementation with pre­ and/probiotics 
could have an important role in inhibiting the generation of key nephrovascular toxins [90].
Considering the potential of all these preparations in shifting the uremic toxin expression 
and also in delaying the CKD progression, the exploration of these novel therapeutic avenues 
could provide vital insights into this inoffensive nutritional therapy.
7. Conclusions and future endeavors
Persistent, low­grade inflammation has been recently accepted as a potential hallmark of 
CKD, playing an essential role in its pathophysiology and being involved as well in the car-
diovascular complications and all-cause poor prognosis in these patients. There has been an 
ascending growth of interest regarding the role of inflammation in CKD and end­stage renal 
disease, which shifts the perception of inflammation as no longer a new, but rather a tradi-
tional risk factor for CKD morbidity and mortality.
The increasing evidence regarding the tight cross talk between inflammation and kidney 
function became pathophysiologically relevant in patients with CKD, due to the development 
of proteomics, genomics, and other omics, and the advancements in state-of-the-art technolo-
gies for identification of novel biomarkers in renal diseases. The complex mechanisms in CKD 
development and progression would require not a single marker, but assessment of a panel of 
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biomarkers in order to enhance all types of alterations that characterize such a complex and 
insidious disease.
A variety of novel interventions have been recently proposed to target inflammation in CKD, and 
it seems that, in the near future, the conventional biomarkers could be proficiently improved, or 
even replaced with novel ones; however, confirmation of their efficacy, sensitivity, and specific-
ity will definitely require randomized controlled and adequately interventional clinical trials.
Growing evidence indicates that gut microbiota can be considered as a recently discovered 
“organ,” being involved in different pathological axes, in relation with almost every organ, includ-
ing kidneys. Recent advances indicate that gut dysbiosis confers unexpected health risks. The gut-
kidney axis has imposed itself in the renal diseases scenario as a novel therapeutic avenue with 
great potential in the forthcoming future. Emerging evidences highlight the possible correlation 
between dysbiosis and a wide range of diseases. The gut microbiota imbalance represents though 
the plausible missing link between nutrition and health, focusing on CKD. Alterations in gut 
microbiota and a myriad of host responses have been involved in CKD prognosis, high risk of car-
diovascular complications, uremic toxicity, and inflammation. There is a vicious circle in CKD, in 
which, on one hand, toxic gut microbiota metabolites are the major circulating uremic toxins and, 
on the other hand, their aggregation deteriorates gut dysbiosis and promotes CKD progression.
This novel promising field of research could lead, in the near future, to the design of remark-
ably personalized nutritional procedures, in order to design the most convenient dietary 
strategy for each individual.
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